Clinical Trial Update: Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study of KPT-330 (selective inhibitor of nuclear export) in advanced hematological cancers completed; results available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Drugs mentioned

• KPT-330

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Hematological Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2021-04-01